Table 1.
Demographic and clinical data in patients with JIA and control for TL and JIA and controls for PWV
| JIA | Controls (TL) | P | Controls (PWV) | P | |
|---|---|---|---|---|---|
| n = 24 | n = 21 | n = 20 | |||
| Age (years) | 15,5 ± 6,3 | 11,4 ± 1,3 | 0, 005a | 13,8 ± 5,9 | 0,184a |
| Gender - n (%) | |||||
| Male | 7 (26,1) | 8 (40,9) | 0,460b | 6 (30) | 0,458b |
| Female | 17(73,9) | 13 (59,1) | 14 (70) | ||
| Ethnics - n (%) | |||||
| Caucasian | 19 (82,6) | 17(81,8) | 1, 000c | 16 (80) | 0,640c |
| Black | 5 (17,4) | 4 (18,2) | 4 (20) | ||
| Weight (Kg) | 50,1 ± 17,5 | 42,5 ± 10,2 | 0, 085a | 46,8 ± 13,7 | 0,528a |
| Height (m) | 1,52 ± 0,17 | 1,47 ± 0,09 | 0, 162a | 1,44 ± 1,09 | 0,473a |
| BMI (KG/m2) | 20,7 ± 3,7 | 19,6 ± 2,7 | 0, 247a | 18,2 ± 4,9 | 0,372a |
| Duration disease (years) [P25 - P75] | 9 [5–19] | ||||
| Subtype – n (%) | |||||
| Oligoarticular | 15 (65,2) | ||||
| Polyarticular | 8 (34,8) | ||||
| Medications – n(%) | |||||
| Corticoids | 8 (34,8) | ||||
| NSAIDS | 0(0,0) | ||||
| Methotrexate | 12 (52,2) | ||||
| Leflunomide | 10 (43,5) | ||||
| Anti-TNF | 7 (30,4) | ||||
| Uveitis – n (%) | 1 (4,3) | ||||
NSAIDS Nonsteroidal anti-inflammatory drugs, Anti-TNF Anti-tumour necrosis factor alpha agent
a T-student test; b Pearson test; c Fisher test